ExpreS2ion Biotechnologies: First Patient Dosed in Phase 1 Clinical Trial of ES2B-C001
23 juni, 15:31
23 juni, 15:31
ExpreS2ion today announced that the first patient has been dosed with ES2B-C001, and the treatment was well tolerated. This successful dosing marks the transition of the trial from the enrollment phase to the treatment phase
23 juni, 15:31
ExpreS2ion today announced that the first patient has been dosed with ES2B-C001, and the treatment was well tolerated. This successful dosing marks the transition of the trial from the enrollment phase to the treatment phase
Rapportperioden
Plejd
Inflationen
Rapportperioden
Plejd
Inflationen
OMX Stockholm 30
1 DAG %
Senast
2 532,42
SEB
Idag, 07:14
SEB:s VD om resultatet: "Solitt"